Plus Therapeutics, Inc.
Plus Therapeutics, Inc. (PSTV) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
pstv · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Plus Therapeutics, Inc. (PSTV) measures how much investors pay for each dollar of the company's trailing earnings. PSTV's current PE ratio of N/A is calculated by dividing its stock price of $5.53 by its TTM earnings per share of -$1.80.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Plus Therapeutics, Inc.You PSTV | $13M | N/A | — | -$1.80 |
 AN2 Therapeutics, Inc. ANTX | $105M | N/A | — | -$1.16 |
 Boundless Bio, Inc. BOLD | $32M | N/A | — | -$2.60 |
 Intensity Therapeutics, Inc. INTS | $7M | N/A | — | -$0.86 |
 Iterum Therapeutics plc ITRM | $2M | N/A | — | -$1.26 |
 Jasper Therapeutics, Inc. JSPR | $8M | N/A | — | -$3.95 |
 NextCure, Inc. NXTC | $7M | N/A | — | -$19.65 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-7.19 | — | |
2024-12-31 FY2024 | — | $-48.86 | — | |
2023-12-31 FY2023 | — | $-105987.89 | — | |
2022-12-31 FY2022 | — | $-289584.94 | — | |
2021-12-31 FY2021 | — | $-416250.39 | — | |
2020-12-31 FY2020 | — | $-697942.67 | — | |
2019-12-31 FY2019 | — | $-2949862.90 | — | |
2018-12-31 FY2018 | — | $-27251941.33 | — | |
2017-12-31 FY2017 | — | $-1313259.38 | — | |
2016-12-31 FY2016 | — | $-31875.09 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Plus Therapeutics, Inc. (PSTV) measures how much investors pay for each dollar of the company's trailing earnings. PSTV's current PE ratio of N/A is calculated by dividing its stock price of $5.53 by its TTM earnings per share of -$1.80.
Frequently asked questions
PSTV pe ratio · 6 questionsPSTV's current PE ratio is N/A as of 2026-06-09, based on a stock price of $5.53 and TTM EPS of -$1.80. Data sourced from Financial Modeling Prep via PSTV's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Plus Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09